Upgrade to SI Premium - Free Trial

Jefferies Downgrades Summit Therapeutics plc (SMMT) to Hold

March 16, 2026 12:50 AM
Jefferies analyst Faisal Khurshid downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Buy to Hold with a price target of $15.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades